Daniel M. Halperin, MD
There have been several therapeutic and research advances made in the management of neuroendocrine tumors (NETs), said Daniel M. Halperin, MD, but perhaps the most exciting development has been the introduction of peptide receptor radionuclide therapy (PRRT).
In January 2018, the FDA approved the radionuclide therapy known as Lutathera (lutetium Lu 177 dotatate) for the treatment of patients with somatostatin receptor–positive gastroenteropancreatic NETs (GEP-NETs). The approval was based on positive results from the phase III NETTER-1 trial, which randomized patients with grade 1/2 metastatic midgut NETs to receive either Lutathera or high-dose octreotide LAR. Initial results revealed a 79% reduction in the risk of progression or death with Lutathera compared with octreotide.1
An updated analysis from the 2018 ASCO Annual Meeting continued to demonstrate a higher proportion of progression-free survival (PFS) events in the octreotide arm compared with the Lutathera arm (HR, 0.21; 95% CI, 0.14-0.33; P
... to read the full story